Biosimilar Development News

  1. Alvotech And Fuji Pharma Extend Biosimilar Partnership In Japan 12/10/2020

    Alvotech and Japanese pharmaceutical company Fuji Pharma announce that they have agreed on an extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. The initial pipeline contains biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan.

  2. New Clinical Trial Data Demonstrates BD Libertas Wearable Injector As A Drug Delivery System 12/9/2020

    BD (Becton, Dickinson and Company), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector.

  3. NantHealth Presents Significant Treatment Insights At The 2020 San Antonio Breast Cancer Symposium In A Time Of Need With The Pandemic’s Impact On Cancer Care 12/9/2020

    NantHealth, Inc., a provider of enterprise solutions that help businesses transform complex data into actionable insights, today presented during a poster session at the San Antonio Breast Cancer Symposium (SABCS) new significant findings around the adoption of trastuzumab biosimilars in the treatment of HER2-positive breast cancer and the potential clinical and cost benefits of biosimilars.

  4. All Routes To Healthcare Efficiency Include Biosimilar Medicines 12/9/2020

    Biosimilar medicines have multiple long term benefits, but policy makers need to act immediately to maximise these, according to new IQVIA data.

  5. Announcement Of Independent Chair 12/9/2020

    As Australia emerges from the current global health and economic crisis, one of the world’s most respected and experienced health policy leaders, Ms Jane Halton AO PSM, is joining Australia’s peak body for generic and biosimilar medicines, as its inaugural Independent Chair.

  6. Valeo Pharma Announces Health Canada Approval For Redesca And Redesca Hp 12/9/2020

    Valeo Pharma Inc. (CSE:VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, announced today that Health Canada has issued a Notice of Compliance for Redesca and Redesca HP low molecular weight heparin ("LMWH") biosimilars.

  7. Henlius Adalimumab Biosimilar Receives Approval Through The NMPA 12/8/2020

    Shanghai Henlius Biotech, Inc. (2696.HK) announced that the biosimilar adalimumab HLX03, independently developed and manufactured by the company, has received approval from the National Medical Products Administration (NMPA) for the treatment of rheumatodid arthritis (RA), ankylosing spondylitis (SA) and plaque psoriasis (Ps).

  8. Agilent Presents Thought Leader Award To IIT Delhi Scientist Professor Anurag Rathore 12/7/2020

    Agilent Technologies Inc. has honored Prof. Anurag Rathore, a scientist at the Indian Institute of Technology (IIT) Delhi, with an Agilent Thought Leader Award, for his contributions to the field of biopharmaceutical research and his work with advanced methods for molecular characterization of biosimilars.

  9. Boehringer Ingelheim Submits Citizen Petition To FDA Concerning Interpretation Of ‘Strength’ In Biologics Price Competition And Innovation Act 12/4/2020

    Boehringer Ingelheim has filed a Citizen Petition asking the Food and Drug Administration (FDA) to correct its interpretation of the term “strength” as used in the Biologics Price Competition and Innovation Act (“BPCIA”).

  10. First Report Card On Biosimilars In Oncology 12/1/2020

    Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor at the George Washington University School of Nursing and Milken Institute School of Public Health, along with researchers at the University of South Carolina, the City of Hope Comprehensive Cancer Center in Duarte, California, the Virginia Mason Cancer Institute and Saint Louis University School of Medicine, identify factors preventing the effective launch of oncology biosimilars in the United States, including the struggle to garner market share and fighting patent litigation lawsuits across the country.